Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics' Shares Soar in April

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Complete Genomics climbed 83 percent in April, after the firm's CEO presented an update on the company's business at a conference and analysts increased their revenue expectations.

Complete Genomics led all shares in the GenomeWeb Daily News Index, which gained 8 percent amid a strong month for the stock market in general, with the Dow Jones Industrial Average up 4 percent, the Nasdaq up 3 percent, and the Nasdaq Biotech Index up 7 percent.

In mid-April, Complete Genomics CEO Clifford Reid said at the Future Leaders in Biotech Industry Conference that the firm shipped 600 genomes to customers in the first quarter of 2011 — a 20 percent increase over estimates that it provided in mid-March. That announcement led several analysts to increase their revenue estimates for the firm.

An announcement early in the month that Laboratory Corporation of America would buy Orchid Cellmark for $85.4 million pushed Orchid's shares up 39 percent for the month. And a report last week that said Gen-Probe had put itself up for sale pushed that firm's shares up 25 percent for the month.

Shares of CombiMatrix climbed 30 percent in April. Early in the month, the firm raised $6.7 million in a private placement. It subsequently announced an agreement under which GE Healthcare's Clarient business had licensed rights to commercialize CombiMatrix's DNA array product portfolio.

Shares of GenMark Diagnostics also had a strong month, rising 26 percent after the firm appointed a new CEO with vast experience in the diagnostics industry.

Of the 11 stocks in the GWDN Index that declined during the month, Rosetta Genomics had the steepest drop, falling 26 percent. The firm announced early in the month that its fourth-quarter revenues had fallen 62 percent year over year, and that it would delay its planned launch of its miRview kidney test for the identification of four histological types of renal tumors, and its miRview meso prognostic for sub-classifying mesothelioma patients.

GWDNIndex0411.jpg

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.